Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

946 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. King B, et al. Among authors: joly p. Am J Clin Dermatol. 2024 Mar;25(2):299-314. doi: 10.1007/s40257-024-00846-3. Epub 2024 Jan 23. Am J Clin Dermatol. 2024. PMID: 38263353 Free PMC article. Clinical Trial.
Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort.
Salle R, Tubach F, Arlegui H, Curmin R, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, De Rycke Y, Jullien D, Mahé E, Paul C, Richard MA, Bachelez H, Zago M, Chosidow O, Sbidian É; PsoBioTeq. Salle R, et al. Among authors: joly p. Clin Exp Dermatol. 2023 Oct 25;48(11):1238-1246. doi: 10.1093/ced/llad233. Clin Exp Dermatol. 2023. PMID: 37409606
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study.
Murrell DF, Caux F, Patsatsi A, Hagino O, Rudnicka L, Vassileva S, Uzun S, Ye J, Yen K, Arora P, Gourlay SG, Joly P, Werth VP. Murrell DF, et al. Among authors: joly p. J Invest Dermatol. 2024 Mar 16:S0022-202X(24)00192-1. doi: 10.1016/j.jid.2024.02.023. Online ahead of print. J Invest Dermatol. 2024. PMID: 38493933 Free article.
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. King B, et al. Among authors: joly p. Am J Clin Dermatol. 2024 May 24. doi: 10.1007/s40257-024-00864-1. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 38789821 No abstract available.
Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
Aubert H, Arlegui H, De Rycke Y, Bachelez H, Beylot-Barry M, Dupuy A, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Sbidian E, Viguier M, Chosidow O, Tubach F, Bénéton N; PsoBioTeq Study Group. Aubert H, et al. Among authors: joly p. Br J Dermatol. 2023 Jan 23;188(1):150-152. doi: 10.1093/bjd/ljac024. Br J Dermatol. 2023. PMID: 36689510 No abstract available.
Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis: A 2-Step Double-Blind Randomized Clinical Trial.
Joly P, Lafon A, Houivet E, Donnadieu N, Richard MA, Dupuy A, Delaporte E, Bernard P, Machet L, Tosti A, Del Marmol V, Grimalt R, de Viragh PA, Benichou J, Chosidow O, Assouly P, Reygagne P. Joly P, et al. JAMA Dermatol. 2023 Apr 1;159(4):403-410. doi: 10.1001/jamadermatol.2022.6687. JAMA Dermatol. 2023. PMID: 36884234 Free PMC article. Clinical Trial.
Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort.
Arlegui H, Mahé E, Richard MA, De Rycke Y, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, Jullien D, Bachelez H, Sbidian É, Chosidow O, Paul C, Tubach F; PSOBIOTEQ study group. Arlegui H, et al. Among authors: joly p. Ann Dermatol Venereol. 2023 Jun;150(2):101-108. doi: 10.1016/j.annder.2023.01.005. Epub 2023 Feb 15. Ann Dermatol Venereol. 2023. PMID: 36914553 Free PMC article.
Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study.
Ou S, Tancrède-Bohin E, Alexandre M, Ingen-Housz-Oro S, Castel M, Debarbieux S, Duvert-Lehembre S, Konstantinou MP, Abasq C, Berthin C, Couzan C, Lepelletier C, Jelti L, Bouteiller J, Calugareanu A, Véron M, Caux F, Joly P, Thomas B, Viguier M; French Study Group on Autoimmune Bullous Skin Diseases. Ou S, et al. Among authors: joly p. J Am Acad Dermatol. 2024 Jan;90(1):204-208. doi: 10.1016/j.jaad.2023.08.101. Epub 2023 Sep 26. J Am Acad Dermatol. 2024. PMID: 37769901 No abstract available.
946 results